MedPath

Sulforaphane

Generic Name
Sulforaphane
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C6H11NOS2
CAS Number
142825-10-3
Unique Ingredient Identifier
GA49J4310U
Background

Sulforaphane is under investigation for the treatment of Autism Spectrum Disorder. It is a naturally occurring isothiocyanate found in high concentration in a variety of broccoli.

Associated Conditions
-
Associated Therapies
-

Safety, Feasibility, and Tolerability of Sulforaphane in Children With Chronic Kidney Disease

Phase 2
Recruiting
Conditions
Pediatric Kidney Disease
Interventions
First Posted Date
2022-12-16
Last Posted Date
2023-08-09
Lead Sponsor
University of Rochester
Target Recruit Count
12
Registration Number
NCT05653492
Locations
πŸ‡ΊπŸ‡Έ

University of Rochester Medical Center, Rochester, New York, United States

Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES

Phase 1
Recruiting
Conditions
Diastolic Dysfunction
Systolic Dysfunction
Diastolic Heart Failure
Interventions
First Posted Date
2022-06-07
Last Posted Date
2024-11-06
Lead Sponsor
Texas Tech University Health Sciences Center
Target Recruit Count
200
Registration Number
NCT05408559
Locations
πŸ‡ΊπŸ‡Έ

Texas Tech University Health Sciences Center (TTUHSC), Lubbock, Texas, United States

Sulforaphane Use to Effect Inflammatory and Metabolic Changes in Virally Suppressed HIV Patients

Phase 4
Conditions
HIV Infections
Interventions
Other: Placebo
Drug: Sulforaphane
First Posted Date
2022-02-04
Last Posted Date
2022-02-07
Lead Sponsor
Sunshine Specialty Health Care
Target Recruit Count
20
Registration Number
NCT05224492

Study of Sulphoraphane in Chronic Kidney Disease

Phase 1
Completed
Conditions
Chronic Kidney Disease stage3
Chronic Kidney Disease stage4
Interventions
First Posted Date
2021-12-10
Last Posted Date
2024-08-12
Lead Sponsor
University of Rochester
Target Recruit Count
18
Registration Number
NCT05153174
Locations
πŸ‡ΊπŸ‡Έ

University of Rochester Medical Center, Rochester, New York, United States

A 6-month Study to Evaluate Sulforaphane Effects in PD Patients

Phase 2
Recruiting
Conditions
Parkinson Disease
Interventions
Drug: Placebo
Drug: Sulforaphane
First Posted Date
2021-10-19
Last Posted Date
2023-07-06
Lead Sponsor
Central South University
Target Recruit Count
100
Registration Number
NCT05084365
Locations
πŸ‡¨πŸ‡³

Mental Health Institute of Second Xiangya Hospital,CSU, Changsha, Hunan, China

A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia Patients

Phase 2
Completed
Conditions
Schizophrenia
Interventions
Dietary Supplement: placebo
Drug: Sulforaphane
First Posted Date
2020-08-21
Last Posted Date
2023-04-26
Lead Sponsor
Central South University
Target Recruit Count
125
Registration Number
NCT04521868
Locations
πŸ‡¨πŸ‡³

Second Xiangya Hospital, Changsha, Hunan, China

Effects of Sulforaphane on Cognitive Function in Patients With Frontal Brain Damage

Phase 2
Conditions
Frontal Lobe Dysfunction
Interventions
Drug: placedo
Drug: sulforaphane
First Posted Date
2020-02-05
Last Posted Date
2020-05-19
Lead Sponsor
Xiangya Hospital of Central South University
Target Recruit Count
90
Registration Number
NCT04252261

A 12-weeks Study to Evaluate Sulforaphane in the Treatment of Depression

Phase 2
Conditions
Depressive Disorder
Interventions
Other: placedo
Drug: sulforaphane
Drug: selective 5 - HT reuptake inhibitors (SSRI)
First Posted Date
2020-01-29
Last Posted Date
2020-08-20
Lead Sponsor
Central South University
Target Recruit Count
90
Registration Number
NCT04246905
Locations
πŸ‡¨πŸ‡³

Mental Health Institute of Second Xiangya Hospital,CSU, Changsha, Hunan, China

Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction

Phase 1
Recruiting
Conditions
Anthracycline Related Cardiotoxicity in Breast Cancer
Interventions
Drug: Placebo Oral Tablet
Drug: sulforaphane
First Posted Date
2019-05-02
Last Posted Date
2024-11-20
Lead Sponsor
Texas Tech University Health Sciences Center
Target Recruit Count
70
Registration Number
NCT03934905
Locations
πŸ‡ΊπŸ‡Έ

Texas Tech University Health Sciences Center, Lubbock, Texas, United States

Effect of Topical Sulforaphane on Skin Fragility Seen in Skin Aging and With Ultraviolet Exposure

Phase 2
Terminated
Conditions
Aging
Interventions
Drug: Sulforaphane
Radiation: Narrow-band Ultraviolet B exposure
Procedure: 4 mm skin punch biopsy
First Posted Date
2017-04-24
Last Posted Date
2023-06-29
Lead Sponsor
Johns Hopkins University
Target Recruit Count
9
Registration Number
NCT03126539
Locations
πŸ‡ΊπŸ‡Έ

Cutaneous Translational Research Program, Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

Β© Copyright 2025. All Rights Reserved by MedPath